RU-28306: Difference between revisions
Appearance
Content deleted Content added
m Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script) |
added Category:Dimethylamino compounds using HotCat |
||
(18 intermediate revisions by 13 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Chemical compound}} |
|||
{{one source|date=October 2014}} |
|||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = |
| IUPAC_name = |
||
| image = RU- |
| image = RU-28306.svg |
||
| width = 180 |
| width = 180 |
||
Line 25: | Line 25: | ||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number_Ref = {{cascite|correct|CAS}} |
|||
| CAS_number = 73625-11-3 |
| CAS_number = 73625-11-3 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| UNII = CT4LCW2PLE |
|||
| ATC_prefix = |
| ATC_prefix = |
||
| ATC_suffix = |
| ATC_suffix = |
||
Line 34: | Line 37: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=13 | H=16 | N=2 |
| C=13 | H=16 | N=2 |
||
⚫ | |||
| molecular_weight = 200.279 g/mol |
|||
⚫ | |||
| StdInChI = 1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3 |
| StdInChI = 1S/C13H16N2/c1-15(2)11-6-9-4-3-5-12-13(9)10(7-11)8-14-12/h3-5,8,11,14H,6-7H2,1-2H3 |
||
| StdInChIKey = BQOANWOQEHVATQ-UHFFFAOYSA-N |
| StdInChIKey = BQOANWOQEHVATQ-UHFFFAOYSA-N |
||
Line 42: | Line 44: | ||
}} |
}} |
||
'''RU-28306''' is a |
'''RU-28306''' is a synthetic [[indole alkaloid]] derivative which acts as a [[serotonin receptor]] agonist, with selectivity for [[5-HT1 receptor|5-HT<sub>1</sub>]] and [[5-HT2 receptor|5-HT<sub>2</sub>]] subtypes. It can be regarded either as a tricyclic derivative of [[Dimethyltryptamine|DMT]], or a structurally simplified analogue of [[LSD]], but the [[binding affinity]] of [[racemic]] RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT<sub>2</sub> subtypes and lower for 5-HT<sub>1</sub>.<ref name="pmid3657392">{{cite journal | vauthors = Taylor EW, Nikam S, Weck B, Martin A, Nelson D | title = Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites | journal = Life Sciences | volume = 41 | issue = 16 | pages = 1961–9 | date = October 1987 | pmid = 3657392 | doi = 10.1016/0024-3205(87)90749-1 }}</ref> It has been sold as a [[designer drug]] and was first reported to the [[EMCDDA]] by a forensic laboratory in Slovenia in 2017.<ref>[http://www.emcdda.europa.eu/system/files/publications/9282/20183924_TDAN18001ENN_PDF.pdf EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA]</ref> |
||
==See also== |
==See also== |
||
* [[4,5-DHP-DMT]] |
* [[4,5-DHP-DMT]] |
||
* [[Bay R 1531]] |
* [[Bay R 1531]] |
||
* [[NDTDI]] |
|||
* [[RU-24,969]] |
* [[RU-24,969]] |
||
Line 57: | Line 60: | ||
[[Category:Serotonin receptor agonists]] |
[[Category:Serotonin receptor agonists]] |
||
[[Category:Tryptamines]] |
[[Category:Tryptamines]] |
||
[[Category:Phenethylamines]] |
|||
[[Category:Heterocyclic compounds with 3 rings]] |
|||
[[Category:Indoles]] |
|||
[[Category:Dimethylamino compounds]] |
Latest revision as of 08:11, 19 September 2023
Identifiers | |
---|---|
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H16N2 |
Molar mass | 200.285 g·mol−1 |
3D model (JSmol) | |
| |
|
RU-28306 is a synthetic indole alkaloid derivative which acts as a serotonin receptor agonist, with selectivity for 5-HT1 and 5-HT2 subtypes. It can be regarded either as a tricyclic derivative of DMT, or a structurally simplified analogue of LSD, but the binding affinity of racemic RU-28306 is closer to that of DMT, though with relatively higher affinity for 5-HT2 subtypes and lower for 5-HT1.[1] It has been sold as a designer drug and was first reported to the EMCDDA by a forensic laboratory in Slovenia in 2017.[2]
See also
[edit]References
[edit]- ^ Taylor EW, Nikam S, Weck B, Martin A, Nelson D (October 1987). "Relative selectivity of some conformationally constrained tryptamine analogs at 5-HT1, 5-HT1A and 5-HT2 recognition sites". Life Sciences. 41 (16): 1961–9. doi:10.1016/0024-3205(87)90749-1. PMID 3657392.
- ^ EMCDDA – Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA